An Open-Label, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Advanced Solid Tumors or Advanced Lymphoma/Myeloma Patients with Mild, Moderate, and Severe Renal Impairment

被引：0
|
作者：
Kelly, Kevin R. [1 ]
Gabrail, Nashat Y. [2 ]
Edenfield, William J. [3 ]
Lockhart, A. Craig [4 ]
Olszanski, Anthony J. [5 ]
Reddy, Guru [6 ]
机构：
[1] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
[2] Gabrail Canc Ctr, Canton, OH USA
[3] Canc Ctr Carolinas, Greenville, SC USA
[4] Washington Univ, Sch Med, St Louis, MO 63130 USA
[5] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
[6] Spectrum Pharmaceut, Irvine, CA USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment
    Kevin R. Kelly
    Nashat Gabrail
    Steven Weitman
    John Sarantopoulos
    Anthony J. Olszanski
    William Edenfield
    Jurgen Venitz
    Guru Reddy
    Allen Yang
    Steven J. Hasal
    A. Craig Lockhart
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 929 - 939
  • [2] Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment
    Kelly, Kevin R.
    Gabrail, Nashat
    Weitman, Steven
    Sarantopoulos, John
    Olszanski, Anthony J.
    Edenfield, William
    Venitz, Jurgen
    Reddy, Guru
    Yang, Allen
    Hasal, Steven J.
    Lockhart, A. Craig
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (05) : 929 - 939
  • [3] A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment
    Saif, Muhammad Wasif
    Becerra, Carlos R.
    Fakih, Marwan G.
    Sun, Weijing
    Popovic, Lazar
    Krishnamurthi, Smitha
    George, Thomas J.
    Rudek, Michelle A.
    Shepard, Dale R.
    Skopek, Jiri
    Sramek, Vladimir
    Zaric, Bojan
    Yamamiya, Ikuo
    Benhadji, Karim A.
    Hamada, Kensuke
    He, Yaohua
    Rosen, Lee
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (03) : 485 - 497
  • [4] A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment
    Muhammad Wasif Saif
    Carlos R. Becerra
    Marwan G. Fakih
    Weijing Sun
    Lazar Popovic
    Smitha Krishnamurthi
    Thomas J. George
    Michelle A. Rudek
    Dale R. Shepard
    Jiri Skopek
    Vladimir Sramek
    Bojan Zaric
    Ikuo Yamamiya
    Karim A. Benhadji
    Kensuke Hamada
    Yaohua He
    Lee Rosen
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 485 - 497
  • [5] Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
    Gordon, Michael S.
    Nemunaitis, John
    Barve, Minal
    Wainberg, Zev A.
    Hamilton, Erika P.
    Ramanathan, Ramesh K.
    Sledge, George W., Jr.
    Yue, Huibin
    Morgan-Lappe, Susan E.
    Blaney, Martha
    Kasichayanula, Sreeneeranj
    Motwani, Monica
    Wang, Lan
    Naumovski, Louie
    Strickler, John H.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 1988 - 1995
  • [6] A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI)
    Renouf, D. J.
    Hirte, H. W.
    O'Bryant, C. L.
    Trnkova, Z. J.
    Cleton, A.
    Huang, F.
    Mueller, U.
    Ayoub, J-P.
    Lockhart, A. C.
    Quinn, D. I.
    Dy, G. K.
    Sawyer, M. B.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] A Multicenter, Open-Label, Phase 1 Study Evaluating the Safety and Tolerability of Pegaspargase in Combination with Gemcitabine in Advanced Metastatic Solid Tumors and Lymphoma
    Borad, Mitesh J.
    Babiker, Hani M.
    Anthony, Stephen
    Mita, Monica
    Buchbinder, Aby
    Keilani, Taha
    Grem, Jean
    CANCER INVESTIGATION, 2015, 33 (05) : 172 - 179
  • [8] Cardiovascular safety of pimitespib in patients with advanced solid tumors: An open-label, nonrandomized, phase 1 study
    Naoki, Katsuhiko
    Igawa, Satoshi
    Uojima, Haruki
    Tsumura, Hideyasu
    Sengoku, Norihiko
    Karayama, Masato
    Shimomura, Akihiko
    Ohtake, Tohru
    Shio, Yutaka
    Hosokawa, Ayumu
    Komatsu, Yoshito
    Kumagai, Yuji
    CANCER, 2024, 130 (21) : 3745 - 3756
  • [9] Phase 1 open-label study evaluating pharmacokinetics, safety, and tolerability of linifanib in Japanese patients with solid tumors
    Tamura, Tomohide
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Asahina, Hajime
    Shibata, Takashi
    Goto, Yasushi
    Tanioka, Maki
    Tamura, Yosuke
    Seki, Yoshitaka
    Chiu, Yi-Lin
    Gupta, Neeraj
    Carlson, Dawn
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [10] A phase 1, open-label, dose-escalation study of pralatrexate incombination with bortezomib in patients with relapsed/refractory multiple myeloma
    Dunn, Tamara J.
    Dinner, Shira
    Price, Elizabeth
    Coutre, Steven E.
    Gotlib, Jason
    Hao, Ying
    Berube, Caroline
    Medeiros, Bruno C.
    Liedtke, Michaela
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 253 - 259
12345